A recent report by the Government Accountability Office (GAO) has revealed a shocking truth: the Food and Drug Administration (FDA) rarely exercises its power to recall dangerous medical devices, leaving patients vulnerable to potential harm. This issue came to light following an investigation into the 2021 recall of breathing machines, which affected millions of Americans.
ProPublica and the Pittsburgh Post-Gazette exposed the FDA's failure to act on hundreds of complaints received over several years regarding these machines. Despite the potential risks, the FDA never ordered a recall, leaving it to Philips Respironics to take action. The devices, fitted with an industrial foam, could release toxic materials into patients' lungs, including those of the elderly, veterans, and infants.
Philips received thousands of additional complaints before initiating the recall, and alarmingly, they did not notify the FDA. Customers who relied on these machines reported various health issues, from respiratory illnesses to kidney and liver conditions, and even cancer.
The FDA's Lack of Action: A Troubling Trend
In 2023, U.S. Senators Dick Durbin and Richard Blumenthal urged the GAO to investigate the FDA's practices in light of this major recall. The GAO's findings were damning: the FDA has not used its authority to force manufacturers to recall defective devices in decades, with the last such action taken in 1992. Instead, device makers voluntarily initiate recalls, with around 900 recalls occurring each year over the past five years.
Even when companies start the recall process, the FDA's staff, which has faced significant cuts, often cannot ensure that the process is carried out efficiently. This includes delays in removing defective devices and effectively communicating with consumers.
The FDA currently regulates over 190,000 medical devices in the U.S., an increase from 2016, yet it seems ill-equipped to handle this responsibility. Senator Blumenthal emphasized the need for additional resources and staff to protect Americans from unsafe devices, warning that future staffing cuts will only worsen the situation.
The Impact on Patients: A Slow and Dangerous Process
The investigation revealed that some patients were unaware of the 2021 recall for months or even years, continuing to use the potentially harmful devices. The FDA has received over 500 reports of deaths associated with these devices since 2021, highlighting the urgency of the issue.
Dr. Rita Redberg, a cardiologist and medical device safety expert, criticized the FDA's recall notification system as "primitive" and in need of significant improvement. She pointed out the absurdity of the FDA relying on faxed recall notices, lacking a modern data infrastructure.
A former FDA official expressed concern that recent staffing cuts could further hinder the agency's ability to handle recalls efficiently. FDA employees reported being unable to perform basic tasks, such as reading status reports from companies during recalls, which detail the progress and impact of the recall process.
The Response and Proposed Solutions
In response to the GAO's report, the Department of Health and Human Services (HHS) has committed to assessing the need for additional staff and legislative authority to better manage recalls. The FDA has defended its handling of the Philips recall, stating it acted promptly upon learning of safety concerns.
Philips, the manufacturer, has reached agreements with the Justice Department and settled lawsuits, promising to improve safety measures and pay over $1 billion in compensation.
Senator Durbin and Representative Jan Schakowsky have introduced legislation to address the GAO's concerns. The bill aims to require the FDA to establish an electronic recall alert system, ensuring better communication between companies, the FDA, hospitals, and doctors.
"Millions of Americans rely on medical devices for their health, and when these devices are recalled, patients deserve to know immediately to understand the risks," Senator Durbin emphasized.
This issue raises important questions about the FDA's role in protecting public health and the need for improved oversight and communication in the medical device industry.
